Bavarian Nordic A/S (CPSE: BAVA)
Health Care · Biotechnology · DK
Dkr230.00
+3.05% today · -2.8% 1Y
Bavarian Nordic A/S (CPSE: BAVA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.53B and employs 1,906 people.
Over the last twelve months the share price has lost 2.8%, trading between 171.30 and 243.70.
Tweenvest scores Bavarian Nordic A/S across four factors: quality 70/100, value 33/100, growth 83/100. Its strongest factor is growth.
BAVA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.53B
- Revenue (TTM)
- $968.53M
- P/E
- 11.50
- EPS
- 19.42
- Dividend yield
- —
- Beta (5Y)
- 0.97
- 52-week high
- Dkr243.70
- 52-week low
- Dkr171.30
- Avg volume (3M)
- —
- Shares outstanding
- 75.71M
- Employees
- 1,906
- Next earnings
- —
About Bavarian Nordic A/S
Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in the research, production, and global distribution of vital, life-saving vaccines. The company's commercialized offerings include non-replicating vaccines for smallpox and monkeypox, marketed as IMVAMUNE, IMVANEX, and JYNNEOS. Additionally, their portfolio features Rabipur/RabAvert for rabies prevention, Encepur for tick-borne encephalitis, and MVABEA, an Ebola vaccine. Bavarian Nordic also maintains a robust pipeline of investigational treatments. This includes MVA-BN (freeze-dried), which has successfully completed Phase III clinical trials for smallpox; MVA-BN RSV, currently in Phase III development for respiratory syncytial virus; ABNCoV2, which completed Phase II trials targeting SARS-CoV-2; and TAEK-VAC, presently in Phase I/II trials for advanced HER2 and brachyury-expressing cancers. The firm engages in key partnerships, notably a license and collaboration agreement with AdaptVac, and licensing agreements with both the National Cancer Institute and the Public Health Service. Bavarian Nordic operates across a wide international footprint, with a presence in countries such as the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and numerous other global markets.
- ISIN
- DK0015998017
- Founded
- 1992
- Listed since
- Jan 3, 2000
- Exchange
- OMX Nordic Exchange Copenhagen
- Currency
- DKK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| BioArctic AB (publ)OM: BIOA B | $2.70B | Skr305.20 | -2.55% |
| BGI Genomics Co., Ltd.SZSE: 300676 | $2.62B | CN¥45.86 | +1.64% |
| Sinocelltech Group LimitedSHSE: 688520 | $2.60B | CN¥37.05 | +3.64% |
| Zealand Pharma A/SCPSE: ZEAL | $2.54B | Dkr237.00 | -4.97% |
| Disc Medicine, Inc.NasdaqGM: IRON | $2.48B | $60.77 | -5.80% |
| Beam Therapeutics Inc.NasdaqGS: BEAM | $2.48B | $24.60 | -0.69% |
| Celldex Therapeutics, Inc.NasdaqCM: CLDX | $2.39B | $29.30 | -3.71% |
| Nurix Therapeutics, Inc.NasdaqGM: NRIX | $2.39B | $22.21 | -3.39% |
Figures last refreshed Oct 4, 2026.